Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Boehringer Ingelheim
McKinsey
Baxter
AstraZeneca

Last Updated: August 19, 2022

Investigational Drug Information for LEE011


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for LEE011?

LEE011 is an investigational drug.

There have been 81 clinical trials for LEE011. The most recent clinical trial was a Phase 3 trial, which was initiated on March 23rd 2022.

The most common disease conditions in clinical trials are Breast Neoplasms, Neoplasms, and Carcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).

There are one hundred and seventy-eight US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for LEE011
TitleSponsorPhase
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid TumorsInnovative Therapies For Children with Cancer ConsortiumPhase 1/Phase 2
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid TumorsNovartis PharmaceuticalsPhase 1/Phase 2
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNovartis PharmaceuticalsPhase 1/Phase 2

See all LEE011 clinical trials

Clinical Trial Summary for LEE011

Top disease conditions for LEE011
Top clinical trial sponsors for LEE011

See all LEE011 clinical trials

US Patents for LEE011

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LEE011 See Plans and Pricing Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH) See Plans and Pricing
LEE011 See Plans and Pricing Ribociclib intermediate and preparation method therefor SUZHOU MIRACPHARMA TECHNOLOGY CO., LTD. (Suzhou, CN) See Plans and Pricing
LEE011 See Plans and Pricing Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer Novartis AG (Basel, CH) See Plans and Pricing
LEE011 See Plans and Pricing Compounds and compositions as inhibitors of MEK Novartis AG (Basel, CH) See Plans and Pricing
LEE011 See Plans and Pricing Androgen receptor mutation Novartis AG (Basel, CH) See Plans and Pricing
LEE011 See Plans and Pricing Methods of treating cancer patients with farnesyltransferase inhibitors Kura Oncology, Inc. (La Jolla, CA) See Plans and Pricing
LEE011 See Plans and Pricing Heterocyclic estrogen receptor modulators and uses thereof Genentech, Inc. (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LEE011

Drugname Country Document Number Estimated Expiration Related US Patent
LEE011 Australia AU2014348657 2033-11-13 See Plans and Pricing
LEE011 Australia AU2017245411 2033-11-13 See Plans and Pricing
LEE011 Australia AU2019246853 2033-11-13 See Plans and Pricing
LEE011 Brazil BR112016010716 2033-11-13 See Plans and Pricing
LEE011 Canada CA2929181 2033-11-13 See Plans and Pricing
LEE011 China CN105899232 2033-11-13 See Plans and Pricing
LEE011 Eurasian Patent Organization EA201690987 2033-11-13 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Boehringer Ingelheim
McKinsey
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.